A committee of experts from the National Pharmaceutical Pricing Authority has determined the retail prices of four different strength drugs for diabetes. Prices of drugs with a fixed dose combination of depagliflozine and metformin hydrochloride have been fixed. This step has been taken to ensure that every consumer benefits from the expiration of the patent expiration date of Depaglyflozine and that diabetes medications become cheaper.
A fixed dose combination of diabetes with a strength of 5 mg and a combination of metformin hydrochloride with a strength of XR 1000 costs Rs. A retail price of 7.54 has been fixed. It does not include goods and services tax. Similarly, the retail price of a tablet of a fixed dose combination of 10 mg of Depaglyflozine and XR 1000 mg of Metformin Hydrochloride is Rs. 11.30 has been fixed. It does not include GST. GST will be levied on it separately.
GST will be applicable separately
Similarly, the retail price of one tablet with the above fixed dose combination i.e. Depaglyflozine 10 mg and Metformin Hydrochloride XR 500 mg is Rs. 9.78 has been determined. In addition to these prices, the Goods and Services Tax will be levied at the rate fixed by the government. Similarly, 5 mg of Depaglyphlozin and 500 mg of Metformin Hydrochloride XR with a strength of fixed dose combination cost Rs. 6.25 has been fixed. It will be subject to separate GST.
Read In Gujarati
The last day for the patent on depaglyphlozine was October 2, 2020. As a result, companies other than those who invented the drug can now market it by making drugs from it. The decision was taken at a meeting of the NPPA-National Pharmaceuticals Pricing Authority on June 21. The two companies had applied to the NPPA to fix the retail price of the drug. The two companies are MSN Laboratories and Cyanochem Pharmaceuticals and JB Chemicals and Mankind Pharma.
NPP's effort to ensure that patients benefit from the reduction
In a previous meeting held in December 2020, the retail price of drugs of different strengths with a fixed dose combination of depagliflozin and metformin was also fixed by the Drug Price Controller. The NPP is trying to ensure that patients benefit from the reduction in the price of drugs released from patent limits.
Prices for drugs with a fixed dose combination of metformin and vildigliptin were set in December 2020. At this price, retailers were also allowed to get a profit of 16 per cent. Companies have to provide details of all expenses in the form insurance to determine the price. The price of a drug is determined on the basis of these details. Its retail price is determined by adding the profits of wholesalers and retailers.
0 Comments